Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$2.97 - $4.84 $676,583 - $1.1 Million
-227,806 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$4.08 - $14.75 $951,798 - $3.44 Million
-233,284 Reduced 50.59%
227,806 $979,000
Q4 2020

Feb 12, 2021

BUY
$11.06 - $14.01 $646,678 - $819,164
58,470 Added 14.52%
461,090 $5.1 Million
Q3 2020

Nov 12, 2020

SELL
$10.26 - $14.55 $571,020 - $809,780
-55,655 Reduced 12.14%
402,620 $4.87 Million
Q2 2020

Aug 14, 2020

SELL
$7.11 - $13.76 $1.15 Million - $2.23 Million
-162,091 Reduced 26.13%
458,275 $6.31 Million
Q1 2020

May 15, 2020

SELL
$5.71 - $15.85 $1.66 Million - $4.6 Million
-290,451 Reduced 31.89%
620,366 $4.8 Million
Q4 2019

Feb 14, 2020

SELL
$9.6 - $17.75 $4.87 Million - $9.01 Million
-507,557 Reduced 35.78%
910,817 $13.9 Million
Q3 2019

Nov 14, 2019

SELL
$12.16 - $21.0 $611,234 - $1.06 Million
-50,266 Reduced 3.42%
1,418,374 $17.3 Million
Q2 2019

Aug 13, 2019

BUY
$9.44 - $19.8 $4.62 Million - $9.68 Million
489,087 Added 49.93%
1,468,640 $29.1 Million
Q1 2019

May 15, 2019

BUY
$11.11 - $13.49 $665,677 - $808,280
59,917 Added 6.52%
979,553 $12 Million
Q4 2018

Feb 13, 2019

SELL
$10.24 - $15.49 $1.47 Million - $2.22 Million
-143,632 Reduced 13.51%
919,636 $11.7 Million
Q3 2018

Nov 13, 2018

SELL
$15.53 - $19.97 $2.12 Million - $2.73 Million
-136,597 Reduced 11.38%
1,063,268 $16.5 Million
Q2 2018

Aug 10, 2018

SELL
$15.88 - $19.5 $4.4 Million - $5.4 Million
-276,792 Reduced 18.74%
1,199,865 $22.4 Million
Q1 2018

May 11, 2018

BUY
$13.53 - $17.47 $11.4 Million - $14.7 Million
843,364 Added 133.17%
1,476,657 $25.1 Million
Q4 2017

Feb 14, 2018

BUY
$14.41 - $19.15 $9.13 Million - $12.1 Million
633,293
633,293 $10.1 Million

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.